Company: Bloom Science Inc.
Job title: Chief Executive Officer & Co-Founder, Director
Evaluating a Next Generation LBP Therapy for Patients with Dravet and ALS 12:45 pm
IrisRx – a platform for mechanistic based LBP drug development Rational selection of BL-001 strains in drug-resistant epilepsy and ALS Results of a pilot study with BL-001 in healthy volunteersRead more
day: Day One Track A AM